Companies: 10,795·Total market cap: $144.5T
Cidara Therapeutics, Inc.

Cidara Therapeutics, Inc.

CDTXNASDAQHealthcare
$221.38
+$0.00(+0.00%)
Market Cap$5.6B
P/E Ratio
52W High$221.42
52W Low$15.22

Cidara Therapeutics, Inc. (CDTX) Cash on Hand — Cash & Short-Term Investments

Cash & cash equivalents plus short-term investments from the balance sheet, YoY change, and net cash vs debt context.

CDTX · cash on hand · updated Dec 31, 2024

Core cash position

Cash & Short-Term Investments (CCE + ST Investments)
$189.8M +430.6% vs prior year
FY · as of Dec 31, 2024 · Reported in USD
Cash & Cash Equiv. (CCE)
$189.8M
cashAndCashEquivalents
Short-Term Investments
$0
shortTermInvestments
YoY Change vs Prior Year
+430.6%
vs prior fiscal year
Latest Quarter
$293.7M
Q3 2025
Data Scope & Methodology

Cash on Hand = Cash & Cash Equivalents (CCE) + Short-Term Investments, as reported on the balance sheet (10-K/10-Q). Also referred to as cash reserves or cash position. Not free cash flow.

Source: FMP /balance-sheet-statement · SEC 10-K / 10-Q · Reported in USD

Source: FMP /balance-sheet-statement · SEC 10-K / 10-Q · USDUpdated: December 31, 2024

Net cash vs debt

Cash & ST Investments$189.8MCash on Hand
Total Debt$3.6MTotal Debt
Net Cash / Net Debt+$186.2MNet Cash Position
Cash vs Debt Ratio
Cash 98%Debt 2%

Cidara Therapeutics, Inc. has a net cash position of $186.2M, holding more cash than debt.

Net Cash = Cash & ST Investments − Total Debt$189.8M$3.6M = +$186.2M

Cash on hand history

YoY Increase
YoY Decrease
Latest Year
CDTX annual cash on hand history · Cash & Short-Term Investments · Source: FMP /balance-sheet-statement

Annual cash on hand by year

DateCash & ST InvestmentsYoY Change
Dec 31, 2024Latest$189.8M+430.6%
Dec 31, 2023$35.8M+9.3%
Dec 31, 2022$32.7M-47.4%
Dec 31, 2021$62.3M+73.4%
Dec 31, 2020$35.9M-28.6%
CDTX cash on hand annual historical data · Cash & Short-Term Investments per balance sheet (10-K/10-Q) · Reported in USD · Source: FMP /balance-sheet-statement

Healthcare Sector Cash Reserves Comparison

#CompanyCash & ST Inv.Cash/MCap
#1
UnitedHealth Group Incorporated
UnitedHealth Group Incorporated
UNH
$28.12B7.6%
#2
Johnson & Johnson
Johnson & Johnson
JNJ
$20.10B3.6%
#3
Eli Lilly and Company
Eli Lilly and Company
LLY
$7.27B0.7%
#4
AbbVie Inc.
AbbVie Inc.
ABBV
$5.26B1.3%
#5
Cidara Therapeutics, Inc.
Cidara Therapeutics, Inc.YOU
CDTX
$189.8M3.4%
Healthcare sector cash reserves · Source: FMP /balance-sheet-statement + /profile · Sorted by Cash desccompanies with most cash on hand →

About cash on hand & methodology

Cidara Therapeutics, Inc. (CDTX) cash on hand as of December 31, 2024 is $189.8M, comprising $189.8M in cash and cash equivalents (CCE) plus $0 in short-term investments — reported as Cidara Therapeutics, Inc. cash and short-term investments on the balance sheet (10-K filing). Also referred to as Cidara Therapeutics, Inc. cash reserves or cash position.

Cidara Therapeutics, Inc. annual cash on hand history shows increased +430.6% in 2024: increased +430.6% in 2024. Cidara Therapeutics, Inc. cash reserves in 2024 reflect the company's capital allocation strategy.

Cidara Therapeutics, Inc. carries total debt of $3.6M against cash of $189.8M, resulting in a net cash position of +$186.2M. For the full balance sheet, see the Financials → Balance Sheet tab.

Figures tie to SEC 10-K/10-Q balance sheet disclosures and FMP /balance-sheet-statement where noted.

Frequently asked questions

CDTX cash on hand · 5 questions

As of December 31, 2024, Cidara Therapeutics, Inc. (CDTX) has $189,825,000 in cash on hand — defined as cash and short-term investments on the balance sheet. This includes $189,825,000 in cash and cash equivalents (CCE) plus $0 in short-term investments. Latest quarter (September 30, 2025): $293,651,000. Data sourced from the annual 10-K filing via FMP.

CDTX cash on handCDTX cash reservesCDTX cash 2024how much cash does CDTX have

Source: FMP /balance-sheet-statement · US GAAP · Cidara Therapeutics, Inc. · Cidara Therapeutics, Inc. SEC 10-K & 10-Q filings · US GAAP · Last updated: December 31, 2024